Selected research
Industry Research
Aminoglycosides Antibiotics Drug Industry Research Report 2026
Market perspective
The global Aminoglycosides Antibiotics Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Aminoglycosides Antibiotics Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Aminoglycosides Antibiotics Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Aminoglycosides Antibiotics Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Aminoglycosides Antibiotics Drug include Teva, Novartis, Pfizer, Fresenius Kabi, Sun Pharma, Lannett Company, Jemicare, Hikma and Fangyuan-pharma, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Aminoglycosides Antibiotics Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Aminoglycosides Antibiotics Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Aminoglycosides Antibiotics Drug Market by Company
Teva
Novartis
Pfizer
Fresenius Kabi
Sun Pharma
Lannett Company
Jemicare
Hikma
Fangyuan-pharma
Cipla
Aike Pharmaceutical
Aminoglycosides Antibiotics Drug Segment by Type
Etimicin
Neomycin
Tobramycin
Gentamicin
Amikacin
Others
Aminoglycosides Antibiotics Drug Segment by Application
Hospital
Clinic
Others
Aminoglycosides Antibiotics Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Aminoglycosides Antibiotics Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Aminoglycosides Antibiotics Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Aminoglycosides Antibiotics Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Aminoglycosides Antibiotics Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Etimicin
- Neomycin
- Tobramycin
- Gentamicin
- Amikacin
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Teva
- Novartis
- Pfizer
- Fresenius Kabi
- Sun Pharma
- Lannett Company
- Jemicare
- Hikma
- Fangyuan-pharma
- Cipla
- Aike Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Aminoglycosides Antibiotics Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Etimicin
- 2.2.3 Neomycin
- 2.2.4 Tobramycin
- 2.2.5 Gentamicin
- 2.2.6 Amikacin
- 2.2.7 Others
- 2.3 Aminoglycosides Antibiotics Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Aminoglycosides Antibiotics Drug Breakdown Data by Type
- 3.1 Global Aminoglycosides Antibiotics Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Aminoglycosides Antibiotics Drug Forecasted Market Size by Type (2027-2032)
4 Aminoglycosides Antibiotics Drug Breakdown Data by Application
- 4.1 Global Aminoglycosides Antibiotics Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Aminoglycosides Antibiotics Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Aminoglycosides Antibiotics Drug Market Perspective (2021-2032)
- 5.2 Global Aminoglycosides Antibiotics Drug Growth Trends by Region
- 5.2.1 Global Aminoglycosides Antibiotics Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Aminoglycosides Antibiotics Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Aminoglycosides Antibiotics Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Aminoglycosides Antibiotics Drug Market Dynamics
- 5.3.1 Aminoglycosides Antibiotics Drug Industry Trends
- 5.3.2 Aminoglycosides Antibiotics Drug Market Drivers
- 5.3.3 Aminoglycosides Antibiotics Drug Market Challenges
- 5.3.4 Aminoglycosides Antibiotics Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Aminoglycosides Antibiotics Drug Players by Revenue
- 6.1.1 Global Top Aminoglycosides Antibiotics Drug Players by Revenue (2021-2026)
- 6.1.2 Global Aminoglycosides Antibiotics Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Aminoglycosides Antibiotics Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Aminoglycosides Antibiotics Drug Head Office and Area Served
- 6.4 Global Aminoglycosides Antibiotics Drug Players, Product Type & Application
- 6.5 Global Aminoglycosides Antibiotics Drug Manufacturers Established Date
- 6.6 Global Aminoglycosides Antibiotics Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Aminoglycosides Antibiotics Drug Market Size (2021-2032)
- 7.2 North America Aminoglycosides Antibiotics Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Aminoglycosides Antibiotics Drug Market Size by Country (2021-2026)
- 7.4 North America Aminoglycosides Antibiotics Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Aminoglycosides Antibiotics Drug Market Size (2021-2032)
- 8.2 Europe Aminoglycosides Antibiotics Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Aminoglycosides Antibiotics Drug Market Size by Country (2021-2026)
- 8.4 Europe Aminoglycosides Antibiotics Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Aminoglycosides Antibiotics Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Aminoglycosides Antibiotics Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Aminoglycosides Antibiotics Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Aminoglycosides Antibiotics Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Aminoglycosides Antibiotics Drug Market Size (2021-2032)
- 10.2 South America Aminoglycosides Antibiotics Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Aminoglycosides Antibiotics Drug Market Size by Country (2021-2026)
- 10.4 South America Aminoglycosides Antibiotics Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Aminoglycosides Antibiotics Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Aminoglycosides Antibiotics Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Aminoglycosides Antibiotics Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Aminoglycosides Antibiotics Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Teva
- 12.1.1 Teva Company Information
- 12.1.2 Teva Business Overview
- 12.1.3 Teva Revenue in Aminoglycosides Antibiotics Drug Business (2021-2026)
- 12.1.4 Teva Aminoglycosides Antibiotics Drug Product Portfolio
- 12.1.5 Teva Recent Developments
- 12.2 Novartis
- 12.2.1 Novartis Company Information
- 12.2.2 Novartis Business Overview
- 12.2.3 Novartis Revenue in Aminoglycosides Antibiotics Drug Business (2021-2026)
- 12.2.4 Novartis Aminoglycosides Antibiotics Drug Product Portfolio
- 12.2.5 Novartis Recent Developments
- 12.3 Pfizer
- 12.3.1 Pfizer Company Information
- 12.3.2 Pfizer Business Overview
- 12.3.3 Pfizer Revenue in Aminoglycosides Antibiotics Drug Business (2021-2026)
- 12.3.4 Pfizer Aminoglycosides Antibiotics Drug Product Portfolio
- 12.3.5 Pfizer Recent Developments
- 12.4 Fresenius Kabi
- 12.4.1 Fresenius Kabi Company Information
- 12.4.2 Fresenius Kabi Business Overview
- 12.4.3 Fresenius Kabi Revenue in Aminoglycosides Antibiotics Drug Business (2021-2026)
- 12.4.4 Fresenius Kabi Aminoglycosides Antibiotics Drug Product Portfolio
- 12.4.5 Fresenius Kabi Recent Developments
- 12.5 Sun Pharma
- 12.5.1 Sun Pharma Company Information
- 12.5.2 Sun Pharma Business Overview
- 12.5.3 Sun Pharma Revenue in Aminoglycosides Antibiotics Drug Business (2021-2026)
- 12.5.4 Sun Pharma Aminoglycosides Antibiotics Drug Product Portfolio
- 12.5.5 Sun Pharma Recent Developments
- 12.6 Lannett Company
- 12.6.1 Lannett Company Company Information
- 12.6.2 Lannett Company Business Overview
- 12.6.3 Lannett Company Revenue in Aminoglycosides Antibiotics Drug Business (2021-2026)
- 12.6.4 Lannett Company Aminoglycosides Antibiotics Drug Product Portfolio
- 12.6.5 Lannett Company Recent Developments
- 12.7 Jemicare
- 12.7.1 Jemicare Company Information
- 12.7.2 Jemicare Business Overview
- 12.7.3 Jemicare Revenue in Aminoglycosides Antibiotics Drug Business (2021-2026)
- 12.7.4 Jemicare Aminoglycosides Antibiotics Drug Product Portfolio
- 12.7.5 Jemicare Recent Developments
- 12.8 Hikma
- 12.8.1 Hikma Company Information
- 12.8.2 Hikma Business Overview
- 12.8.3 Hikma Revenue in Aminoglycosides Antibiotics Drug Business (2021-2026)
- 12.8.4 Hikma Aminoglycosides Antibiotics Drug Product Portfolio
- 12.8.5 Hikma Recent Developments
- 12.9 Fangyuan-pharma
- 12.9.1 Fangyuan-pharma Company Information
- 12.9.2 Fangyuan-pharma Business Overview
- 12.9.3 Fangyuan-pharma Revenue in Aminoglycosides Antibiotics Drug Business (2021-2026)
- 12.9.4 Fangyuan-pharma Aminoglycosides Antibiotics Drug Product Portfolio
- 12.9.5 Fangyuan-pharma Recent Developments
- 12.10 Cipla
- 12.10.1 Cipla Company Information
- 12.10.2 Cipla Business Overview
- 12.10.3 Cipla Revenue in Aminoglycosides Antibiotics Drug Business (2021-2026)
- 12.10.4 Cipla Aminoglycosides Antibiotics Drug Product Portfolio
- 12.10.5 Cipla Recent Developments
- 12.11 Aike Pharmaceutical
- 12.11.1 Aike Pharmaceutical Company Information
- 12.11.2 Aike Pharmaceutical Business Overview
- 12.11.3 Aike Pharmaceutical Revenue in Aminoglycosides Antibiotics Drug Business (2021-2026)
- 12.11.4 Aike Pharmaceutical Aminoglycosides Antibiotics Drug Product Portfolio
- 12.11.5 Aike Pharmaceutical Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst